Literature DB >> 33956048

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.

Yoel Angel1,2, Avishay Spitzer2,3,4, Oryan Henig2,5, Esther Saiag2,6, Eli Sprecher2,7,8, Hagit Padova2,9, Ronen Ben-Ami2,5.   

Abstract

IMPORTANCE: Randomized clinical trials have provided estimates of the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 infection, but its effect on asymptomatic infections remains unclear.
OBJECTIVE: To estimate the association of vaccination with the Pfizer-BioNTech BNT162b2 vaccine with symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. DESIGN, SETTING, AND PARTICIPANTS: This was a single-center, retrospective cohort study conducted at a tertiary medical center in Tel Aviv, Israel. Data were collected on symptomatic and asymptomatic SARS-CoV-2 infections confirmed via polymerase chain reaction (PCR) tests in health care workers undergoing regular screening with nasopharyngeal swabs between December 20, 2020, and February 25, 2021. Logistic regression was used to calculate incidence rate ratios (IRRs) comparing the incidence of infection between fully vaccinated and unvaccinated participants, controlling for demographics and the number of PCR tests performed. EXPOSURES: Vaccination with the BNT162b2 vaccine vs unvaccinated status was ascertained from the employee health database. Full vaccination was defined as more than 7 days after receipt of the second vaccine dose. MAIN OUTCOMES AND MEASURES: The primary outcome was the regression-adjusted IRR for symptomatic and asymptomatic SARS-CoV-2 infection of fully vaccinated vs unvaccinated health care workers. The secondary outcomes included IRRs for partially vaccinated health care workers (days 7-28 after first dose) and for those considered as late fully vaccinated (>21 days after second dose).
RESULTS: A total of 6710 health care workers (mean [SD] age, 44.3 [12.5] years; 4465 [66.5%] women) were followed up for a median period of 63 days; 5953 health care workers (88.7%) received at least 1 dose of the BNT162b2 vaccine, 5517 (82.2%) received 2 doses, and 757 (11.3%) were not vaccinated. Vaccination was associated with older age compared with those who were not vaccinated (mean age, 44.8 vs 40.7 years, respectively) and male sex (31.4% vs 17.7%). Symptomatic SARS-CoV-2 infection occurred in 8 fully vaccinated health care workers and 38 unvaccinated health care workers (incidence rate, 4.7 vs 149.8 per 100 000 person-days, respectively, adjusted IRR, 0.03 [95% CI, 0.01-0.06]). Asymptomatic SARS-CoV-2 infection occurred in 19 fully vaccinated health care workers and 17 unvaccinated health care workers (incidence rate, 11.3 vs 67.0 per 100 000 person-days, respectively, adjusted IRR, 0.14 [95% CI, 0.07-0.31]). The results were qualitatively unchanged by the propensity score sensitivity analysis. CONCLUSIONS AND RELEVANCE: Among health care workers at a single center in Tel Aviv, Israel, receipt of the BNT162b2 vaccine compared with no vaccine was associated with a significantly lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection more than 7 days after the second dose. Findings are limited by the observational design.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33956048      PMCID: PMC8220476          DOI: 10.1001/jama.2021.7152

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

1.  What the data say about asymptomatic COVID infections.

Authors:  Bianca Nogrady
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

2.  Asymptomatic SARS-CoV-2 infection.

Authors:  Eng Eong Ooi; Jenny G Low
Journal:  Lancet Infect Dis       Date:  2020-06-12       Impact factor: 25.071

3.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

Review 4.  Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.

Authors:  Daniel P Oran; Eric J Topol
Journal:  Ann Intern Med       Date:  2020-06-03       Impact factor: 25.391

5.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

6.  BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel.

Authors:  Ariel Munitz; Matan Yechezkel; Yoav Dickstein; Dan Yamin; Motti Gerlic
Journal:  Cell Rep Med       Date:  2021-04-18

7.  BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.

Authors:  Shmuel Benenson; Yonatan Oster; Matan J Cohen; Ran Nir-Paz
Journal:  N Engl J Med       Date:  2021-03-23       Impact factor: 91.245

8.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

9.  Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.

Authors:  Seungjae Lee; Tark Kim; Eunjung Lee; Cheolgu Lee; Hojung Kim; Heejeong Rhee; Se Yoon Park; Hyo-Ju Son; Shinae Yu; Jung Wan Park; Eun Ju Choo; Suyeon Park; Mark Loeb; Tae Hyong Kim
Journal:  JAMA Intern Med       Date:  2020-11-01       Impact factor: 21.873

10.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.

Authors:  Anne Kimball; Kelly M Hatfield; Melissa Arons; Allison James; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Zeshan Chisty; Jeneita M Bell; Mark Methner; Josh Harney; Jesica R Jacobs; Christina M Carlson; Heather P McLaughlin; Nimalie Stone; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Denny Russell; Brian Hiatt; Jessica Gant; Jeffrey S Duchin; Thomas A Clark; Margaret A Honein; Sujan C Reddy; John A Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-03       Impact factor: 17.586

View more
  77 in total

1.  Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases.

Authors:  Richard Paul Junghans
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

2.  Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.

Authors:  Scott Sibbel; Katherine McKeon; Jiacong Luo; Karl Wendt; Adam G Walker; Tara Kelley; Rachael Lazar; Meredith L Zywno; Jeffrey J Connaire; Francesca Tentori; Amy Young; Steven M Brunelli
Journal:  J Am Soc Nephrol       Date:  2021-11-17       Impact factor: 10.121

3.  To Boost or Not to Boost Residents and Fellows-That Is the Question.

Authors:  Sofia Zavala; Kathryn M Andolsek; Jason E Stout
Journal:  J Grad Med Educ       Date:  2022-08

Review 4.  Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic.

Authors:  Yutong Wang; Ke Zheng; Wenjing Gao; Jun Lv; Canqing Yu; Lan Wang; Zijun Wang; Bo Wang; Chunxiao Liao; Liming Li
Journal:  Med Rev (Berl)       Date:  2022-02-24

5.  A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan.

Authors:  Hiroyuki Noda
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

6.  Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.

Authors:  Avishay Spitzer; Yoel Angel; Or Marudi; David Zeltser; Esther Saiag; Hanoch Goldshmidt; Ilana Goldiner; Moshe Stark; Ora Halutz; Ronni Gamzu; Marina Slobodkin; Nadav Amrami; Eugene Feigin; Meital Elbaz; Moran Furman; Yotam Bronstein; Amanda Chikly; Anna Eshkol; Victoria Furer; Talia Mayer; Suzy Meijer; Ariel Melloul; Michal Mizrahi; Michal Yakubovsky; Dana Rosenberg; Ari Safir; Liron Spitzer; Eyal Taleb; Ori Elkayam; Adi Silberman; Tali Eviatar; Ofir Elalouf; Tal Levinson; Katia Pozyuchenko; Ayelet Itzhaki-Alfia; Eli Sprecher; Ronen Ben-Ami; Oryan Henig
Journal:  JAMA       Date:  2022-01-25       Impact factor: 157.335

7.  SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels.

Authors:  Heba H Mostafa; Chun Huai Luo; C Paul Morris; Maggie Li; Nicholas J Swanson; Adannaya Amadi; Nicholas Gallagher; Andrew Pekosz
Journal:  medRxiv       Date:  2021-07-07

8.  Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.

Authors:  Thomas Harder; Judith Koch; Sabine Vygen-Bonnet; Wiebe Külper-Schiek; Antonia Pilic; Sarah Reda; Stefan Scholz; Ole Wichmann
Journal:  Euro Surveill       Date:  2021-07

9.  The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.

Authors:  Daisuke Jubishi; Koh Okamoto; Kensuke Hamada; Takashi Ishii; Hideki Hashimoto; Takayuki Shinohara; Marie Yamashita; Yuji Wakimoto; Amato Otani; Naoko Hisasue; Mahoko Ikeda; Sohei Harada; Shu Okugawa; Kyoji Moriya; Shintaro Yanagimoto
Journal:  Hum Vaccin Immunother       Date:  2022-03-25       Impact factor: 4.526

10.  Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.

Authors:  Chia Siang Kow; Syed Shahzad Hasan
Journal:  Inflammopharmacology       Date:  2021-07-09       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.